Nanexa AB (publ)

The time is 12.30, and if you're not already out for lunch, you're here to watch when Nexa has released their report for Q2 2022. I have with me the CEO, David Westberg. A warm welcome. Thank you. If we start by going through the numbers a little quickly. You reported a somewhat declining turnover from last year. Last year you reported 7.7. This quarter, you reported 5.7. If you look at the turnover loss, it also drops, from 10 million to now 6.1 million. Phase 1 study initiated, can you summarize more about the quarter?

Yes, absolutely. This with the revenues is really a It's a variable that differs from quarter to quarter, so there's not much to comment on. We have a slightly lower provision of the already pre-paid income we have from Novo Nordisk, which doesn't have anything to do with the project itself, more in terms of bookkeeping. The cost of the moving capital or the moving result has improved somewhat, so to speak, and that is due to the fact that we have lowered costs significantly during this quarter and will do so in the future as well. What more did you say? It was another question. That we initiated phase 1. That we initiated a phase 1 study. Yes, that is what we see as the most fun this quarter. We received approval from the German Medical Association and were able to start the study. We also see that the first cohort has gone very well so that we can go up to the next cohort.

And of course we will talk about all that. There have been a lot of questions, but I think I will start by asking questions about the FAS-1 study. A clear highlight, and I could tell you a little more about the study. How many patients do you have in the current situation and what is the timeline?